A041702-Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

June 10, 2019
https://clinicaltrials.gov/ct2/show/NCT03737981
Cancer - Leukemia
Principal Investigator: Ding Wang, MD
Chronic Lymphocytic Leukemia (CLL), chronic leukemia, leukemia older adults, leukemia
Open